At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 121 enrolled
Drug / intervention
lerapolturev +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (Lerapolturev) in Recurrent WHO Grade IV Malignant Glioma Patients
In Brief
A Phase 2 clinical trial evaluating lerapolturev and Lomustine for Malignant Glioma. Completed, enrolled 121 participants across 6 sites.
Detailed Summary
This is a phase 2 study of lerapolturev, an oncolytic polio/rhinovirus recombinant, in adult patients with recurrent World Health Organization (WHO) grade IV malignant glioma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Glioma
CountriesUnited States
CollaboratorsDuke University
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartJun 2017
Primary CompletionSep 2022
Study CompletionFeb 2023
TodayJul 2026
First PostedDec 8, 2016
Enrollment StartJun 1, 2017
Primary CompletionSep 30, 2022
Study CompletionFeb 3, 2023
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 9.6 years ago
Interventions
lerapolturevbiological
A single dose of lerapolturev, an oncolytic polio/rhinovirus recombinant
Lomustinedrug
one cycle of oral lomustine